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Abstract
Insulin- like growth factor ( IGF-II ) is overexpressed in a
variety of human tumors and has both mitogenic and
antiapoptotic activity. Although themechanisms of IGF-
II– induced proliferation have been well studied, the
mechanisms underlying its survival signaling have been
less well characterized. In this report, we investigated
the role of IGF- II on cisplatin- induced apoptosis. We
found that IGF-II overexpression was associated with
an increase in p70 ribosomal protein S6 kinase (p70
S6K). Cisplatin treatment of C2C12 mouse myoblasts
led to cell death associated with an inhibition of p70 S6K
activity. Endogenous or exogenous IGF-II addition to
C2C12 cells caused protection to cisplatin- induced
apoptosis. This protection was associated in both cases
with an increase in p70 S6K basal activity as well as
resistance to cisplatin - induced decreased activity.
Blockade of p70 S6K activation by rapamycin abrogated
the IGF- II–mediated protection of cells to cisplatin-
induced apoptosis. Furthermore, treatment of IGF- II–
overexpressing Rh30 and CTR rhabdomyosarcoma
cells with rapamycin restored sensitivity to cisplatin-
induced apoptosis. These data together suggest that
IGF - II –associated protection to cisplatin - induced
apoptosis is mediated through an activation of the p70
S6K pathway. Thus, inhibition of the p70 S6 pathway
may enhance chemotherapy- induced apoptosis in the
treatment of IGF-II–overexpressing tumors.
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Introduction
Growth factors act through activation of specific trans-
membrane receptors to elicit regulation of cell growth and
differentiation. This, in turn, triggers a variety of intracellular
signaling pathways that ultimately control cell physiology.
Insulin- like growth factor - II ( IGF-II ) is a paternally
expressed, maternally imprinted, embryonic growth pro-
moter and cell survival factor that plays a major role in cell
growth, survival, differentiation, and development [1,2]. It is
widely believed that IGF-II exerts its effects through the
IGF-I receptor, a ligand-activated tyrosine protein kinase
with high homology to the insulin receptor [3 ], and these
effects are modulated by a family of specific IGF-binding
proteins [4,5 ].
Elevated levels of IGF-II have been detected in many
tumor types and likely promote cell proliferation through
endocrine and paracrine/autocrine signaling [6–8]. We have
previously shown that forced overexpression of IGF-II in
C2C12 myoblasts leads to transformed characteristics [9 ].
Furthermore, IGF-II overexpression was associated with a
diminished G1 checkpoint after  - irradiation and altered cell -
cycle regulation in these cells [10]. IGF- II also plays an
important role in maintaining cell survival during the transition
from proliferating to terminally differentiating myoblasts [11].
Disruption of IGF-II expression in transgenic mice express-
ing T antigen in pancreatic cells causes a dramatic increase
of  cell tumor apoptosis [12]. These results indicate that
IGF-II acts as a survival factor. The signal transduction
pathways involved in IGF-II–mediated cell survival have not
been fully characterized.
Recent studies have shown that the p70 ribosomal protein
S6 kinase (p70 S6K) plays a critical role in cell growth by
modulating the translation of a family of mRNAs that contain
an oligopyrimidine tract at their transcriptional start, which
encodes components of the protein synthetic apparatus [13].
p70 S6K was first identified as an enzyme that catalyzes the
phosphorylation of the S6 protein, a component of the 40S
subunit of the eukaryotic ribosome [14]. Activation of p70
S6K is triggered by various growth factors. Inhibition of the
kinase activation impedes cell growth and blocks cells in the
G1 phase of the cell cycle [15,16]. Rapamycin blocks p70
S6K activation through inhibition of mammalian target of
rapamycin (mTOR), a large-molecular -weight protein that is
thought to serve as either a lipid or a protein kinase [17,18].
Activation of p70 S6K is accompanied by its phosphorylation
on multiple serine and threonine residues [14,16]. Detailed
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analysis of the correlation between changes in the phos-
phorylation of individual sites in p70 S6K and its activity
suggests that threonine 389 (Thr389) is particularly impor-
tant [14]. The Thr389 Ala mutant is catalytically inactive. The
Thr389 Glu mutant is largely insensitive to rapamycin [19].
Phosphorylation of Thr389 by mTOR has recently been
demonstrated [20]. Taken together, Thr389 is a key target
residue for the rapamycin-sensitive input, which leads to p70
SK activation.
Rapamycin- induced p70 S6K dephosphorylation and
inactivation have been shown to be paralleled by dephos-
phorylation of the eukaryotic initiation factor 4E (elF4E)
binding protein (4E-BP1) [21,22], showing that it is also
downstream of mTOR. Increased phosphorylation of 4E-
BP1 leads to its release from elF4E, allowing the initiation
factor to then interact with the elF4G subunit of the mRNA
cap–binding protein complex [21]. In contrast, dephos-
phorylated 4E-BP1 interacts with elF4E and thereby
inhibits cap structure-dependent protein synthesis and cell
growth [23].
In this study, we examined the signal transduction
pathways involved in IGF- II–mediated skeletal muscle cell
survival. We treated the IGF-II–overexpressing C2C12-
2.7 cells and IGF- II–pretreated C2C12 myoblasts with
cisplatin and compared the effects to vector control
C2C12-1.1 and parental C2C12 cells. The control
C2C12-1.1 and parental C2C12 cells undergo apoptosis
after cisplatin treatment, whereas the IGF-II overexpress-
ing C2C12-2.7 and IGF- II–pretreated C2C12 cells are
relatively resistant to cisplatin - induced apoptosis. The IGF-
II–mediated protection to cisplatin - induced apoptosis was
associated with increased p70 S6 kinase. Treatment of
IGF-II overexpressing mouse myoblast cells (C2C12-2.7)
as well as rhabdomyosarcoma cells (Rh30 and CTR) with
rapamycin, an inhibitor of p70 S6K, restores sensitivity to
cisplatin. Our data imply that IGF-II–mediated antiapop-
totic signaling may be mediated through the p70 S6K
pathway.
Materials and Methods
Cell Cultures and Treatment
The mouse myoblast cells lines, C2C12-1.1 (vector
control ) and C2C12-2.7 ( IGF- II overexpressing), were
generated from the C2C12 cell line by C. P. Minniti and
have previously been described [9]. Rh30 and CTR
rhabdomyosarcoma cells have been described [24]. These
cells were seeded in Dulbecco’s modified Eagle’s medium
(DMEM) containing 10% fetal bovine serum, L-glutamine
(2 mM), penicillin (100 U/ml), streptomycin (100 U/ml).
Where indicated, cells were treated with 25 M cisplatin
(Sigma, St. Louis, MO) at indicated times.
Flow Cytometry
Flow cytometry analysis was performed as has pre-
viously been described in detail [10]. Briefly, confluent cells
were treated as indicated in Figures 1 and 3, washed in
PBS, and fixed in ice-cold 70% ethanol for at least 1 hour
at 48C. After washing in PBS containing 0.1% glucose, cells
were treated with PBS staining buffer containing RNase A
(1 mg/ml), propidium iodide (50 g/ml), and 0.1% glucose
in the dark at 48C for 30 minutes A total of 10,000 cells
were analyzed with a FACScan (Becton, Dickinson, San
Diego, CA).
Western Blotting
Cells were treated as indicated in the figures. Cisplatin
was purchased from Sigma. Rapamycin was obtained from
Calbiochem (La Jolla, CA). IGF-II was supplied from R&D
Systems, (Minneapolis, MN). These cells were lysed in
lysis buffer (20 mM Tris–HCl, pH 7.5; 150 mM sodium
chloride; 1 mM EDTA; 1 mM EGTA; 1% triton; 2.5 mM
sodium pryophosphate; 1 mM  -glycerolphosphate; 1 mM
sodium orthovanadate; 0.5 mM phenylmethylsulfonyl fluo-
ride; 1 g/ml leupeptin). Protein lysates (20–50 g/ lane),
as determined by a Bio-Rad protein assay, were separated
in 10–12% sodium dodecyl sulfate polyacrylamide gel
(SDS-PAGE) and then transferred to polyvinylidene
difluoride membranes (Amersham Pharmacia Biotech,
Piscataway, NJ). Membranes were blocked with 5% nonfat
dried milk in TBS-T (20 mM Tris–HCl, pH 7.5; 8 g/ l of
sodium chloride; 0.1% Tween 20) and then incubated with
primary antibodies against phospho-p70 S6K (Thr389),
p70 S6K, phospho-4E-BP1 (Ser65) (Cell Signaling Tech-
nology, Beverly, MA) and Actin (Amersham Pharmacia
Biotech). Horseradish peroxidase conjugated anti–rabbit Ig
G (Cell Signaling Technology) was used as a secondary
antibody. Protein was visualized using an ECL system
(Amersham Pharmacia Biotech).
Figure 1. Prevention of cell death by IGF - II overexpression. Confluent
C2C12 -1.1 and -2.7 cells were treated with or without cisplatin ( 25 M) in
10% FBS medium at indicated time periods. Attached and floating cells were
collected and analyzed on a FACScan flow cytometer for relative DNA
content. The means±SE of triplicate determinations are shown. *P<0.025;
**P<0.01; ***P<0.001.
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p70 S6 Kinase Assay
C2C12-1.1 and C2C12-2.7 cells were treated with 100
nM rapamycin, or 25 M cisplatin, or both for 16 hours and
then lysed in lysis buffer as described above. Protein
concentrations in cell extracts were determined by a Bio-
Rad protein assay, and an equal amount of protein was used
for each assay. Proteins were immunoprecipitated with anti -
p70 S6K antibody (Cell Signaling Technology) overnight at
48C. The immunocomplex was captured with 20 l of
protein-A agarose (Santa Cruz Biotechnology) for 1 hour
at 48C. The immunoprecipitates were washed three times in
lysis buffer and once in kinase assay buffer (20 mM MOPS,
pH 7.2, 25 mM  -glycerol phosphate, 5 mM EGTA, 1 mM
sodium orthovanadate, 1 mM dithiothreitol ). After washing,
the p70 S6 kinase activity was measured with a p70 S6
kinase assay kit (Upstate Biotechnology, Lake Placid, NY)
by using an S6 kinase peptide (AKRRRLSSLRA) as the
substrate in accordance with the manufacturer’s instructions.
MTT assay
Log-phase cells were harvested and seeded in 96-well
plates (1104 cells /well ). C2C12 cells were pretreated
overnight with a monoclonal antibody against the IGF-I
receptor (IR3) at 1 g/ml (Oncogene Science, Cambridge,
Figure 2. Cisplatin - induced inhibition of p70 S6K phosphorylation is reversed by IGF - II overexpression. (A ) Confluent C2C12 -1.1 and -2.7 cells were treated with
or without 25 M cisplatin in 10% FBS medium at indicated times and then lysed in lysis buffer as described under Materials and Methods. Protein extracts (50 g /
lane ) were separated on 10% SDS-PAGE gels, and subjected to Western blot analysis. Blotting with antibody against actin was used to demonstrate equal protein
loading in each lane. Similar results were achieved in three separate experiments. (B ) Confluent C2C12 -1.1 and -2.7 cells were exposed to rapamycin ( 100 nM), or
cisplatin (25 M), or both for 16 hours in 10% FBSmedium. p70 S6 kinase activity was measured using a peptide substrate (AKRRRLSSLRA ) as described in detail
in Materials and Methods. The p70 S6K activity in C2C12 -1.1 cells was set at 100% as a control. Data are mean±SE (n=5 ).
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MA), incubated with or without 25 ng/ml IGF-II for 1 hour,
and then treated with 25 M cisplatin or 100 nM rapamycin
for 24 hours. Cell survival was determined using the MTT
assay according to the manufacturer’s instructions (Prom-
ega, Madison, WI).
Immunoprecipitation
C2C12 cells were pretreated with 25 ng/ml IGF-II for
1 hour followed by treatment with 25 M cisplatin or 100 nM
rapamycin for 24 hours and then lysed in lysis buffer as
described above. Protein concentrations in cell extracts
were determined by a Bio-Rad protein assay. Proteins
(300 g) were immunoprecipitated with an anti -phos-
hho4E-BP1 (Ser65) antibody (Cell Signaling Technology)
for 4 hours at 48C. The immunocomplex was captured with
20 l of protein-A agarose overnight at 48C. The immu-
noprecipitates were washed three times in a lysis buffer,
resolved on 4–20% SDS-PAGE, and then transferred to a
PVDF membrane. The membrane was blocked with 5%
nonfat dried milk in TBS-T and then incubated with the
primary antibody against phospho4E-BP1 (Ser65). Horse-
radish peroxidase conjugated anti–rabbit Ig G was used
as a secondary antibody. Antigen–antibody complexes
were visualized using ECL system (Amersham Pharmacia
Biotech).
Statistical Analysis
Data are presented as mean±standard error (SE).
Statistical significance was determined using a two-sided
Student’s t test. A P value of <0.05 was considered
significant.
Results
IGF- II Overexpression Protected Cells from Apoptosis
We have previously demonstrated that IGF-II–
overexpressing C2C12-2.7 cells have a diminished G1
checkpoint following DNA damage compared to control
C2C12-1.1 cells. [10] To analyze in more detail the role of
IGF- II as a survival factor, we exposed confluent C2C12-1.1
and C2C12-2.7 cells to cisplatin, an apoptosis - inducing
agent, for varying times. As shown in Figure 1, treatment of
C2C12-1.1 cells with 25 M cisplatin significantly induced
cell death in a time-dependent fashion as determined by
propidium iodide staining and flow cytometry analysis. By
contrast, C2C12-2.7 cells showed a lower incidence of
cisplatin- induced apoptosis. After treatment with 25 M
cisplatin at all time points, there is a clear difference between
the percentage of apoptotic cells of IGF-II– transfected cells
and nontransfected cells (P<0.025 at 24 hours; P<0.01 at
32 hours; P<0.001 at 40 and 48 hours). We treated
additional IGF-II– transfected C2C12 myoblast cell lines,
and similar results were obtained by MTT assay (data not
shown). These data indicate IGF-II overexpression pro-
tects these cells from apoptosis induced by cisplatin.
Inhibition of p70 S6K Induced by Cisplatin Was Reversed by
IGF- II Overexpression
The results demonstrated in Figure 1 prompted us to
evaluate the signal transduction cascades involved in
IGF- II–regulated skeletal muscle cell survival. To deter-
mine whether p70 S6K activation was necessary for IGF-
II–mediated survival signaling, we examined p70 S6K
Figure 3. Rapamycin abrogates the IGF-II –mediated protection of cells to cisplatin-induced apoptosis. (A) C2C12-1.1 and -2.7 cells were preincubated with
rapamycin (100 nM) for 3 hours and then treated with or without cisplatin (25 M) for 24 hours in 10% FBSmedium. Cells were stained with propidium iodide and then
analyzed by flow cytometry as described in Materials and Methods. The area labeled M1 is an apoptotic population, M2 is G1, M3 is S, and M4 is G2/M phase
population. (B) The means±SE of triplicate determinations are shown. *P<0.005; **P>0.05. (C) Cells were preincubated with rapamycin (100 nM) for 3 hours and
then treated with or without cisplatin (25 M) for 24 hours in 10% FBS medium. Cell lysates were subjected to Western blotting with antibodies against phospho-p70
S6K and actin.
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phosphorylation and expression in C2C12-1.1 and C2C12-
2.7 cells treated with cisplatin by Western blotting analysis.
As shown in Figure 2A, p70 S6K phosphorylation was
significantly inhibited by cisplatin after 12 hours treatment in
C2C12-1.1 cells. However, no significant change in the level
of p70 S6K expression was detected in these cells. This
cisplatin effect was not seen in IGF-II overexpressing
C2C12-2.7 cells as well other IGF-II– transfected myoblast
cell lines (data not shown). In contrast to the inhibition of p70
S6 kinase, cisplatin had a limited effect on inhibiting Akt
phosphorylation in C2C12-1.1 or 2.7 cells (data not shown).
In addition, p70 S6K phosphorylation was transiently
increased by cisplatin treatment at 4 hours in both cells,
which may be induced by direct cisplatin -mediated cell
toxicity.
Stimulation of p70 S6K Activity by IGF-II Overexpression
As demonstrated in Figure 2A, inhibition of p70 S6K
phosphorylation by cisplatin in C2C12-1.1 cells was
reversed by IGF-II overexpression. Transfection with IGF-
II strongly induces p70 S6K activation compared with control
cells (data not shown). Furthermore, similar results were
obtained for p70 S6K enzymatic activity, as evaluated by an
in vitro kinase assay. p70 S6K activity was induced more
than two- fold in C2C12-2.7 cells compared to C2C12-1.1
cells (Figure 2B ). Cisplatin and rapamycin were shown to
inhibit p70 S6K activity, respectively, in both cell lines.
However, the activity of p70 S6K was higher in C2C12-2.7
cells compared to C2C12-1.1 cells after treatment with
cisplatin and rapamycin (Figure 2B ). Thus, resistance to
cisplatin- induced apoptosis may reflect a marked increase in
p70 S6K activity stimulated by IGF-II overexpression.
Preincubation of both cell lines with rapamycin (100 nM)
followed by treatment with cisplatin (25 M) resulted in
abolishing the difference on the p70 S6K activity between
C2C12-1.1 and C2C12-2.7 cells (Figure 2B ). Together,
these results show that IGF- II overexpression induces a
significant activation of p70 S6 kinase. Furthermore,
rapamycin prevents activation of p70 S6K associated with
IGF- II overexpression.
The Effect of IGF- II Overexpression on Promoting Cell
Survival Was Blocked by Rapamycin
To further evaluate the role of the p70 S6 kinase in IGF-
II–mediated protection from apoptosis induced by cisplatin,
confluent C2C12-1.1 cells and C2C12-2.7 cells were
treated with rapamycin (100 nM) for 3 hours, followed by
a 24-hour incubation with or without cisplatin (25 M). Cells
Figure 4. Rapamycin abolishes the resistance of Rh30 and CTR rhabdomyosarcoma cells to cisplatin-induced apoptosis. Rh30 and CTR cells were pretreated with
rapamycin (100 nM) for 3 hours and then treated with cisplatin (25 M) for 48 hours in 10% FBS medium. Cells were examined and photographed under light
microscope at 200. The results were representative of three independent experiments.
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were stained with propidium iodide and then analyzed by
flow cytometry. As seen in Figure 3A, the area labeled M1
represents the apoptotic population and the area of the
peak labeled M2 represents the G1 phase population.
Pretreatment of both control and C2C12-2.7 cells with
rapamycin followed by treatment of cisplatin enhanced the
effect of cisplatin - induced apoptosis compared to treatment
with cisplatin alone in both cell lines (16.6% vs 12.5% in
C2C12-1.1 control cells and 13.6% vs 7.4% in C2C12-2.7
cells ). IGF-II–mediated protection to cisplatin in IGF-II–
transfected cells (Figure 2B, P<0.025) was reversed by
pretreatment of these cells with rapamycin (Figure 2B,
P>0.05). Similar data was obtained by MTT assay (data
not shown). Thus, blockade of the p70 S6K pathway
Figure 5. IGF-II rescues C2C12 cells from cisplatin-induced apoptosis and reverses inhibition of p70 S6K phosphorylation induced by cisplatin. (A) C2C12 cells were
treated with or without antibody against the IGF-I receptor (1 g/ml) overnight, and incubated with or without IGF-II (25 ng/ml) for 1 hour, and then treated with
cisplatin (25 M) or rapamycin (100 nM) for 24 hours. Cell viability was determined by MTT assay. Data are mean±SE (n=6). (B) C2C12 cells were treated with or
without IGF-II (25 ng/ml) for 1 hour and then treated with cisplatin (25 M) or rapamycin (100 nM) for 24 hours. Protein extracts (40 g/lane) were separated on 10%
SDS-PAGE, and subjected to Western blot analysis. Blotting with antibody against actin was used to demonstrate equal protein loading in each lane. Similar results
were achieved in two separate experiments.
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abolished IGF-II–mediated protection to cisplatin- induced
apoptosis. In addition, the activation of p70 S6 kinase was
completely inhibited by rapamycin in both cell lines
(Figure 3C ). These results support the role of p70 S6
kinase in IGF-II–mediated antiapoptotic signaling.
Rapamycin Restored Sensitivity of Rhabdomyosarcoma
Cells to Cisplatin
To determine whether rapamycin reversal of IGF-II–
mediated protection from cisplatin seen in mouse myoblasts
would be seen in tumors of skeletal muscle origin, we
examined the rapamycin effect in IGF-II–overexpressing
Rh30 and CTR rhabdomyosarcoma cells. Both Rh30 and
CTR cells were resistant to cisplatin - induced apoptosis.
Pretreatment of these cells with rapamycin for 3 hours
followed by treatment with both rapamycin and cisplatin for
48 hours could abolish the protection of both cell lines to
cisplatin - induced apoptosis (Figure 4). These results indi-
cate that blockade of the p70 S6K pathway by rapamycin
can enhance chemotherapy- induced apoptosis in the treat-
ment of IGF-II–overexpressing rhabdomyosarcomas.
Exogenous IGF- II Rescues C2C12 Cells from
Cisplatin- Induced Apoptosis
To further examine the ability of IGF-II to reverse
cisplatin- induced apoptosis, parental C2C212 cells were
exposed to IGF-II (25 ng/ml) for 1 hour and then treated
with 25 M cisplatin for 24 hours. As demonstrated in
Figure 5A, cells pretreated with IGF- II were relatively
resistant to cisplatin - induced apoptosis compared with
IGF- II–nontreated cells (viability: 90% vs 60%, respec-
tively). In addition, pretreatment with IGF-II partially
protected cells from rapamycin- induced apoptosis. Similar
results were observed in IGF-I– treated cells (data not
shown). Neutralizing the antibody against IGF-IR (IR3)
partially abrogated IGF-II protection against cisplatin-
induced apoptosis (Figure 5A ). Thus, protection by IGF-II
appears to be predominantly mediated through the type I IGF
receptor. Furthermore, in cells treated with IGF- II for 24
hours, IGF-II–stimulated phosphorylation of p70 S6K was
completely inhibited by rapamycin (Figure 5B ). Inhibition of
p70 S6K phosphorylation induced by cisplatin was reversed
by IGF-II pretreatment in C2C12 cells (Figure 5B ). Thus, the
data in IGF-II–treated cells are consistent with that in IGF-
II–overexpressing cells.
Effect of Cisplatin on Inhibiting 4E-BP1 Phosphorylation
Because p70 S6K and elF4E-binding protein 1 (4E-BP1)
both lie downstream of mTOR, we examined the effect of
cisplatin on regulating 4E-BP1 phosphorylation. C2C12 cells
were exposed to IGF- II (25 ng) for 1 hour and then treated
with cisplatin (25 M) or rapamycin (100 nM) for 24 hours
and then harvested for immunoprecipitation and Western
blotting analysis using an anti -phospho4E-BP1 (Ser 65). As
shown in Figure 6A, phosphorylation of 4E-BP1 was
significantly diminished after 24 hours of cisplatin treatment.
As expected, rapamycin almost completely inhibited 4E-
BP1 phosphorylation. However, 4E-BP1 phosphorylation
did not increase on 24 hours of IGF-II treatment. This may
reflect a loss of IGF- II’s ability to stimulate 4E-BP1
phosphorylation over extended periods. We further tested
the effect of cisplatin on inhibiting 4E-BP1 phosphorylation
by Western blotting analysis in IGF- II– transfected and
nontransfected cells. Figure 6B shows that IGF- II– trans-
fected cells have a slight increase in the basal level of 4E-
BP1 phosphorylation compared to IGF- II–nontransfected
cells. Phosphorylation of 4E-BP1 was completely inhibited
by cisplatin on 24-hour treatment in C2C12-1.1 cells.
However, the phosphorylation of 4E-BP1 was still detected
in C2C12-2.7 cells. This result suggests that IGF-II over-
expression correlates with resistance to cisplatin - induced
4E-BP1 hypophosphorylation.
Discussion
Induction of apoptosis is widely believed to be the predom-
inant mechanism by which chemotherapy and radiation kill
Figure 6. Effect of cisplatin on inhibiting 4E-BP1 phosphorylation. (A)
Confluent C2C12 cells were treated with IGF-II (25 ng/ml), cisplatin (25 M),
IGF-II together with cisplatin, and rapamycin (100 nM) for 24 hours. A total of
300 g of cell lysates were immunoprecipitated with phospho-4E-BP1 (Ser65)
antibody followed by Western blot analysis as described in Materials and
Methods. (B) Confluent C2C12-1.1 and C2C12-2.7 cells were treated with
cisplatin (25 M) for 24 hours. Protein extracts (100 g/lane) were separated
on 10% SDS-PAGE, and subjected to Western blot analysis. Blotting with
antibody against actin was used to demonstrate equal protein loading in each
lane. Similar results were achieved in two separate experiments.
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cancer cells. Thus, there is considerable interest in under-
standing the cellular mechanisms that regulate the sensitivity
of cells to therapy- induced apoptosis. In this study, we have
demonstrated that C2C12myoblasts transfected with human
IGF-II cDNA or treated with IGF-II can become resistant to
cisplatin - induced apoptosis compared with IGF- II non-
transfected or untreated cells. Namely, IGF-II protects
skeletal muscle cells from apoptosis induced by cisplatin.
Because survival and death likely represent a balance
between antiapoptotic and proapoptotic signaling, we con-
sidered the possibility that IGF-II mediated cell survival by
increasing antiapoptotic signaling, by decreasing proapop-
totic signaling, or both. The data presented in this report
reveal that p70 S6K activity was strongly induced by IGF-II
overexpression. Thus, cisplatin - induced inhibition of p70
S6K phosphorylation in C2C12-1.1 and C2C12 cells was
inhibited in IGF-II– transfected C2C12-2.7 and IGF-II–
treated cells. Furthermore, pretreatment of cells with
rapamycin increased the sensitivity of these cells to
cisplatin - induced apoptosis. Blockade of the p70 S6K
pathway by rapamycin resulted in abrogating the effect of
IGF-II–mediated protection in C2C12-2.7 cells. These data
suggest that the mechanism of IGF-II–mediated myoblast
survival signaling may be mediated through regulation of p70
S6 kinase activity.
Because most effects of IGF-II are mediated by the IGF-
IR, we evaluated whether blockade of IGF- IR by neutralizing
the antibody against IGF-1R (IR3) could block IGF-II–
induced p70 S6K activation. However, no change in p70 S6K
activity was noted (data not shown). This is not surprising
because this antibody at best inhibits proliferation in
autocrine cells by 50% [25]. Perhaps this is due to partial
agonist activity of the antibody, or due to other factors such
as receptor occupancy.
Recent studies have shown that p70 S6 kinase partic-
ipates in the translation of mRNAs, which contain an
oligopyrimidine tract at their transcriptional start site. This
family of mRNAs encodes many of the components of the
translational apparatus, including ribosomal proteins and
elongation factors. Translation plays an important role in
control of cell growth [26,27]. Rates of protein synthesis are
also coupled to cell -cycle progression because inhibition of
translation leads to arrest of cell growth, generally at the G1
phase [11]. Inhibition of translation in response to DNA
damage could contribute to cell -cycle arrest. Rapamycin has
been shown to inhibit translation of IGF-II [28]. In our study,
rapamycin completely inhibits phosphorylation of p70 S6
kinase in IGF-II– transfected, nontransfected and IGF-II–
treated cells and inhibits about 70% of p70 S6K activity. Our
results are consistent with a recent report demonstrating that
phosphorylation of p70 S6K was inhibited during cisplatin -
induced apoptosis and 60–70% of p70 S6K activity was
inhibited by rapamycin [29]. In addition, rapamycin not only
increased the sensitivity of cells to cisplatin- induced
apoptosis but also diminished the IGF- II–related protective
effect from cisplatin - induced apoptosis. Our previous study
found that cells with IGF-II overexpression had a diminished
G1 checkpoint arrest following DNA damage [10]. Inhibition
of p70 S6K activation has been shown to induce G1 arrest
[15,16]. It has been recently reported that rapamycin
induces G1 arrest and apoptosis in Rh1 and Rh30
rhabdomyosarcoma cell lines and expression of a rapamy-
cin- resistant mTOR prevents G1 arrest and apoptosis
induced by rapamycin [30]. Our data show that treatment
of cells with rapamycin suppressed p70 S6K activation and
induced G1 arrest (Figure 3). These data suggest that
rapamycin- induced G1 arrest and apoptosis are mediated
through its inhibitory effect on mTOR/p70 S6 kinase activity.
Activation of p70 S6 kinase appears to exert its function by
regulating translation and protein biosynthesis to control cell
cycle and survival.
In addition to cisplatin, other DNA-damaging agents,
including etoposide and mitomycin-C, have been recently
reported to inhibit phosphorylation of p70 S6K and 4E-BP1 in
Swiss 3T3 and RAT-1 cells [29]. Our data are in agreement
with these findings. Treatment of cells with cisplatin also led
to inhibition of 4E-BP1 phosphorylation, and 4E-BP1 is a
major regulator of elF-4E–mediated 50 cap mRNA trans-
lation [31]. Thus, inhibition of 4E-BP1 phosphorylation
inhibits cap-dependent translation and is considered per-
missive for apoptosis [32]. However, IGF-II–overexpressing
cells are relatively resistant to cisplatin - induced inhibition of
4E-BP1.
Cisplatin is a widely used chemotherapeutic agent for the
treatment of various malignant tumors [33,34]. Cisplatin
reacts with DNA to form intrastrand and/or interstrand
cross- links of platinum adducts [35]. These lesions are
believed to be essential for the cellular toxicity of cisplatin to
prevent DNA replication and transcription [36]. However,
apoptosis induction by cisplatin should not be related
exclusively to the inhibition in DNA synthesis but additional
mechanisms might trigger induction of this process. San-
chez-Perez [37] has reported that exposure of cells to
cisplatin induces a persistent activation of c-Jun N- terminal
kinase (JNK), but not extracellular signal–related kinase
(ERK), indicating that the JNK signaling pathway may be
involved in the cellular response to cisplatin. In addition,
other genes of interest that have been recently linked to
cisplatin cellular biology include: p21, an inhibitor of the
cyclin-dependent kinases, which can protect some cell types
against DNA damage induced by cisplatin [38]; telomerase,
which is inhibited by cisplatin [39]; NFB, a transcription
factor whose levels are increased after cisplatin treatment
[40]. Understanding the molecular basis of cisplatin -
mediated apoptosis could lead to more effective use of this
compound in cancer therapy.
To our knowledge, this study is the first to link an increase
of p70 S6K activity to IGF-II overexpression. Although the
molecular mechanisms of cisplatin - induced p70 S6K inhib-
ition and IGF-II induced p70 S6K activity are unknown, these
data are of potential clinical importance. IGF-II is widely
expressed in human malignant tumors. Inappropriate over-
expression of IGF- II is a common theme in tumor biology
and may be particularly important to pediatric embryonic
tumors [8]. We examined the effect of cisplatin on IGF-II–
overexpressing Rh30 and CTR rhabdomyosarcoma cells. As
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we expected, both cells were resistant to cisplatin- induced
apoptosis. However, pretreatment with rapamycin aimed at
inhibiting p70 S6 kinase activation enhances the efficacy of
cisplatin in the treatment of IGF-II–overexpressing rhabdo-
myosarcoma cells (Figure 4). Although cisplatin is widely
used in the treatment of various solid tumors, one of the
major limitations to the use of the drug is the acquisition of
resistance by initially responsive tumors [41]. In general,
drug- induced apoptosis is dependent on the balance
between cell -cycle checkpoints and DNA-repair mecha-
nisms [42]. Thus, inhibition of the p70 S6k pathway may be
an appropriate target for strategies to overcome the
resistance to chemotherapeutic DNA-damaging drugs and
to provide a therapeutic benefit for the treatment of IGF-II–
overexpressing tumors.
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